Pharma & life sciences: from batch records to digital twins
Hand-written batch records in triplicate. Validation cycles measured in months. The next decade compresses every step of pharma manufacturing.
Before · paper genealogy
For decades, pharma manufacturing was driven by paper-based batch records. Operators signed off each step by hand. Investigations into deviations took weeks. Equipment validation cycles dragged on for months.
The compliance burden was real — for good reason. But the cost was speed and innovation.
Now · GxP electronic everything
Today, electronic batch records, GAMP 5-validated systems, and 21 CFR Part 11-compliant digital signatures are standard. MES platforms enforce process steps automatically. Audit trails are queryable. Investigations close in days, not weeks.
Continuous manufacturing — long resisted by the FDA and EMA — is now widely accepted. Personalised medicine and small-batch biologics depend on it.
The next 10 years · digital-twin compliance
Expect process digital twins that simulate validation runs before steel is bent. AI-driven deviation analysis. Real-time release testing replacing end-of-batch QC. Cell and gene therapy plants that are validated continuously, not at fixed intervals.
Personalised cancer therapies, mRNA platforms, and CAR-T at scale all demand a manufacturing stack that can run a "batch of one" thousands of times a day. The plants that solve this win the next decade.
Written by the team at Karvitech Software Solutions. We build software for shops, clinics, factories, and agencies — across web, mobile, cloud, and the floor.